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OBJECTIVES The objective was to assess the effect of verapamil on atrial fibrillation (AF) cycle length and
spatial dispersion of refractoriness in patients with chronic AF.
BACKGROUND Previous studies have suggested that verapamil prevents acute remodeling by AF. The effects
of verapamil in chronic AF are unknown.
METHODS During electrophysiologic study in 15 patients with chronic AF (duration .1 year), 12
unipolar electrograms were recorded from right atrial free wall, right atrial appendage and
coronary sinus, along with monophasic action potential recordings from the right atrial
appendage. The mean fibrillatory interval at each atrial recording site was used as an index for
local refractoriness. Dispersion of refractoriness was calculated as the standard deviation of all
local mean fibrillatory intervals expressed as a percentage of the overall mean fibrillatory
interval. After baseline measurements, verapamil (0.075 mg/kg intravenous in 10 min) was
infused and the measurements were repeated.
RESULTS After administration of verapamil, mean fibrillatory intervals shortened by a mean of 16.6 6
3.3 ms (p , 0.001) at the right free wall, 15.0 6 3.5 ms (p , 0.001) at the appendage and
17.1 6 3.2 ms (p , 0.01) in the coronary sinus. Monophasic action potential duration
decreased by 15.9 6 4.0 ms (p , 0.01). Dispersion of refractoriness increased in all patients
from 3.8 6 0.8 to 5.1 6 1.8 (p , 0.001). A strong correlation between mean fibrillatory
intervals and action potential duration was found, both before and after verapamil.
CONCLUSIONS Verapamil caused shortening of refractoriness and increase in spatial dispersion of refracto-
riness in patients with chronic AF. This implies that verapamil is not useful in reversing the
remodeling process in these patients. (J Am Coll Cardiol 2001;37:1403–7) © 2001 by the
American College of Cardiology
Experimental and human studies have shown that atrial
fibrillation (AF) causes remodeling (1–8), that is, shorten-
ing of the refractory period and increase in spatial dispersion
of refractoriness. Clinical and experimental studies have
shown that the longer AF is allowed to exist, or remodeling
is allowed to continue, the more difficult it becomes to
obtain sinus rhythm (9). Intracellular calcium overload has
been suggested as the mechanism for remodeling. Recent
reports have suggested that calcium entry blockers such as
verapamil prevent remodeling (8,10,11). However, all of
these studies were carried out in models of recent-onset AF.
In addition, despite extensive clinical experience with vera-
pamil, antifibrillatory effects of verapamil have not become
apparent. On the contrary, an earlier study by Shenasa et al.
(12) showed that AF episode duration increased after
verapamil administration. In addition, a recent experimental
study by Lee et al. (13) showed that verapamil was useless in
preventing remodeling in AF of longer duration. These
authors also showed that verapamil increases atrial vulner-
ability and the duration of induced AF episodes. The
present study was performed to assess the effect of verapamil
on atrial fibrillation cycle length and spatial dispersion of
refractoriness in patients with chronic AF.
METHODS
Patients. We studied 15 consecutive patients (average age
64.8 6 14.2 years, eight females) with chronic AF (duration
of permanent AF .1 year). The underlying etiologies for
AF were idiopathic (three patients), mitral valve disease
(five patients), postinfarct (three patients), idiopathic dilated
cardiomyopathy (two patients) and hypertension (two pa-
tients). The reason for electrophysiologic study was His
bundle ablation for drug-refractory AF in 14 patients and
diagnosis in one patient. All antiarrhythmic drugs had been
discontinued for at least five half-lives and no patient was on
amiodarone. All patients gave informed consent and the
study was approved by the hospital ethical review board.
Study protocol. Electrophysiologic study was performed in
the fasting nonsedated state. Femoral venous access was
obtained using local anesthesia. In all patients, a decapolar
electrode catheter (interelectrode spacing 5 mm) was posi-
tioned against the right lateral free wall as described
previously (14). In the first eight patients, a quadripolar
catheter was positioned in the right atrial appendage. In
these patients, arterial pressure and right atrial pressure were
continuously measured. In the final seven patients, the
quadripolar catheter was positioned in the coronary sinus
(CS) and a quadripolar Franz catheter (EPT, Sunnyvale,
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California) was used to record monophasic action potentials
from the right atrial appendage. Twelve unipolar electro-
grams (filter 0.05 to 500 Hz) were recorded from the
decapolar catheter and the two proximal electrodes from the
quadripolar catheters (14). The catheters were positioned to
obtain a minimum of eight electrogram recordings with
amplitude .0.5 mV. The atrial electrograms, surface leads
(I, II, III, V1), pressure tracings and monophasic action
potentials were recorded using an electrophysiological sys-
tem (Cardiolab, Prucka Engineering, Houston, Texas).
A 3-min period of AF was acquired. Verapamil
(0.075 mg/kg) was then administered intravenously in
10 min. One minute after completion of verapamil infusion,
another 3 min of fibrillatory electrograms were acquired.
Data analysis. The technique used to measure fibrillatory
intervals and to calculate spatial dispersion of refractoriness
has been described previously (14). Fibrillatory intervals
were measured by detecting the intrinsic negative deflec-
tions. For each atrial recording site, histograms of fibrilla-
tory intervals were plotted. Undersensing of intrinsic deflec-
tions was detected by observation of secondary peaks in the
histogram. Such intervals were discarded (15). The mean
fibrillatory interval at each recording site was used as an
index for local refractoriness (16). Dispersion of refractori-
ness was measured by calculating the coefficient of disper-
sion. This was defined as the standard deviation of the mean
of all mean local fibrillatory intervals expressed as a percent-
age of the overall mean fibrillatory interval (14). Electro-
grams from the Franz catheter were used to measure
monophasic action potential durations (APD90) before and
after verapamil administration (17).
Statistical analysis. At each individual recording site,
fibrillatory intervals and APD90 before and after verapamil
were compared using Student t test. Pre- and postverapamil
mean fibrillatory intervals, mean APD90, arterial and right
atrial pressures for the total patient group were compared
using a paired t test. Correlation coefficients between local
fibrillatory interval and APD90 were calculated both before
and after verapamil. A p value of #0.05 was considered
statistically significant.
RESULTS
In each patient, mean fibrillatory intervals significantly
shortened at all individual atrial recording sites after vera-
pamil (Fig. 1, Table 1). The average drop in AF cycle length
was 16.6 6 3.3 ms (p , 0.001) at the right free wall, 15.0 6
3.5 ms (p , 0.001) at the appendage and 17.1 6 3.2 ms
(p , 0.001) in the CS. The shortening of fibrillatory
intervals is further demonstrated in Figure 2, which shows
histograms at a single recording site before and after
verapamil. The histogram shape remains unchanged despite
Abbreviations and Acronyms
AF 5 atrial fibrillation
APD90 5 monophasic action potential duration
CS 5 coronary sinus
Figure 1. Electrogram recordings before (left) and after (right) verapamil administration. The electrograms from the decapolar catheter at the right atrial
free wall are designated E1 to E10; those from the coronary sinus CS1 to CS4 and the monophasic action potential recording MAP. The mean fibrillatory
interval shortened at each recording site. The signal quality in E1 was inadequate for measurement of fibrillatory intervals. This recording site was excluded
from the analysis.
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the shortening of fibrillatory intervals. Data per individual
patient are shown in Table 2. Decrease in mean fibrillatory
intervals per recording site and a decrease in monophasic
action potential duration in the right atrial appendage were
highly significant. As shown in Figure 3, there was a strong
correlation between APD90 and local mean fibrillatory
interval both before and after verapamil administration (r 5
0.989; p , 0.001 and r 5 0.990; p , 0.001, respectively).
The relationship between APD90 and local mean fibrillatory
interval remained unchanged by verapamil. Dispersion of
mean fibrillatory intervals in the right atrium increased
significantly as shown in Table 1. No significant differences
were found between free wall, appendage and CS. Arterial
pressure and right atrial pressure did not change signifi-
cantly in any patient.
DISCUSSION
To our knowledge, this is the first study in patients with
chronic AF to assess the acute effects of verapamil on AF
cycle length and spatial dispersion of refractoriness. Vera-
pamil caused a decrease in mean fibrillatory intervals and an
increase in spatial dispersion. This study suggests that
verapamil does not reverse remodeling in chronic atrial
fibrillation. Finally, verapamil did not alter the linear rela-
tionship between AF cycle length and APD90, suggesting
that verapamil does not alter the excitable gap during AF.
Verapamil in atrial fibrillation. Atrial fibrillation is be-
lieved to produce electrophysiologic changes in the atrial
myocardium, known as remodeling, which in turn facilitate
the perpetuation of AF (1–8). This phenomenon has been
attributed to intracellular calcium overload (8,10,11,18).
Recent studies have suggested that verapamil prevents
remodeling caused by pacing-induced AF (8,10,11). All of
these studies were performed in models of recent-onset AF.
However, antifibrillatory effects of verapamil have not been
demonstrated in a clinical setting.
In an earlier study Shenasa et al. (12) administered
verapamil both intravenously and orally in a maintenance
dose to patients for treatment of supraventricular tachycar-
dia. The duration of electrically induced AF episodes
significantly increased after both intravenous and oral vera-
pamil administration. At the time of that study, this finding
remained unexplained. In a recent study, Lee et al. (13)
demonstrated that verapamil was unable to prevent remod-
eling after one and six weeks of pacing-induced AF in a
canine model. In addition, verapamil increased the duration
of induced AF episodes. Lee et al. (13) also showed that
atrial conduction velocity remained unchanged by verapamil
administration. The present study showed that verapamil
caused shortening of atrial refractoriness in patients. There-
fore, the wavelength of reentrant wavelets, being the prod-
uct of conduction velocity and refractoriness, would also
become shorter (1). This would in turn promote AF
perpetuation. This conclusion is supported by several studies
that have demonstrated increased AF duration caused by
shortened refractoriness (1,5–8,10). Thus, the verapamil-
induced shortening of atrial refractoriness as found in our
study may be the underlying mechanism of the increased
AF duration.
Several studies reported increased atrial vulnerability after
verapamil administration (19). In a previous study by our
group in patients without structural heart disease (14),
dispersion of refractoriness was measured using the same
catheter-based technique described in the present study.
Atrial vulnerability was assessed using a staged stimulation
protocol starting with single extrastimuli followed by more
Figure 2. Histograms of fibrillatory intervals before and after verapamil
administration at a single atrial recording site. The administration of
verapamil caused shortening of fibrillatory intervals without changing the
distribution of these fibrillatory intervals. Black bar 5 control; white bar 5
verapamil.
Table 1. Comparison of Electrophysiologic and Hemodynamic Data Before and After Verapamil
Baseline Verapamil Change p
AF CL at right atrial free wall (ms) 146 6 19 129 6 14 16.6 6 3.3 , 0.001
AF CL at right atrial appendage (ms) 145 6 18 130 6 19 15.0 6 3.5 , 0.001
AF CL in CS (ms) 142 6 12 125 6 9 17.1 6 3.2 0.001
APD90 (ms) 117 6 13 101 6 15 15.9 6 4.0 0.001
Dispersion of refractoriness 3.9 6 0.8 6.3 6 2.1 2.3 6 0.6 , 0.001
Mean arterial pressure (mm Hg) 108 6 13 104 6 16 25.3 6 6.1 NS
Right atrial pressure (mm Hg) 5.3 6 2.1 5.1 6 1.8 0.5 6 0.7 NS
Mean fibrillatory intervals and APD90 decreased in all patients at all recording sites. Dispersion at the right atrial free wall
increased in all patients. There were no significant changes in arterial and right atrial pressure.
AF 5 atrial fibrillation; APD90 5 monophasic action potential duration; CL 5 cycle length; CS 5 coronary sinus.
1405JACC Vol. 37, No. 5, 2001 Ramanna et al.
April 2001:1403–7 Verapamil and Chronic Atrial Fibrillation
aggressive pacing to induce AF. Increased dispersion of
refractoriness was strongly associated with increased atrial
vulnerability. An increase in dispersion of refractoriness as
found in the present study after verapamil administration
may explain the increased atrial vulnerability found in
experimental studies.
Methodological considerations. Mean fibrillatory inter-
vals were used as an index for local refractory periods. This
method, validated in previous studies (16,17,20,21), is the
only practical technique to simultaneously evaluate changes
of refractoriness at multiple sites in patients with chronic
AF. Every patient provided his or her own control data for
comparison with data obtained after verapamil administra-
tion.
Some drugs such as procainamide, flecainide and ibutilide
are known to alter the excitable gap during AF. After
administration of such drugs, AF cycle length no longer
correlates with APD90 and local refractoriness (1,17). In our
patients, however, a strong correlation was observed be-
tween AF cycle length and APD90 both before and after
verapamil administration, as shown in Figure 3. Therefore
the verapamil-induced decrease in fibrillatory cycle length
would be more likely to be caused by a decrease in refractory
period rather than a change in excitable gap.
Autonomic blockade was not used in the present study
because beta-blockade in combination with verapamil was
considered potentially hazardous for the studied patients.
Verapamil effects may be mediated through a sympathetic
response caused by verapamil-induced hypotension, as sug-
gested by Friedman et al. (21). These investigators admin-
istered a bolus of verapamil 0.2 mg/kg in an anesthetized
canine preparation. This resulted in a decrease of arterial
pressure and an increase in right atrial pressure, followed by
enhanced sympathetic activity. These authors suggested that
this increased sympathetic activity was solely responsible for
the increased duration of AF episodes and the increased
atrial vulnerability. In our patients, however, the verapamil
dose was much lower (0.075 mg/kg) and was injected slowly
in 10 min. Absence of significant changes in arterial or right
atrial pressures suggested that intense sympathetic activity
did not occur. In addition, Lee et al. (13) reported increased
AF duration after verapamil during autonomic blockade
with propranolol and atropine. These findings suggest that
the mechanism of the increased duration of AF episodes in
our study is not mediated by sympathetic reflex activity.
Mechanistic implications. Several studies have provided
evidence that intracellular calcium overload is the underly-
ing mechanism of electrophysiologic remodeling
Figure 3. Mean fibrillatory interval and action potential duration (APD90)
were measured in the right atrial appendage in seven patients. For each of
these patients, mean fibrillatory interval (x-axis) and APD90 (y-axis) are
plotted both before (black boxes) and after (white boxes) verapamil. Both
mean fibrillatory intervals as well as APD90 shortened significantly in each
patient. The relationship between mean fibrillatory interval and APD90 is
linear both before and after verapamil administration, and the relationship
between both parameters remains unchanged.
Table 2. Verapamil-Induced Changes in AF Cycle Length, APD90 and Dispersion Coefficient
Patient
D RFW
(ms)
D RAA
(ms)
D CS
(ms)
D APD90
(ms) D DC
1 216 6 3.9 218 2.0
2 218 6 4.6 217 2.3
3 218 6 3.2 213 3.2
4 219 6 4.2 215 1.5
5 28 6 2.1 27 1.6
6 212 6 3.1 210 2.1
7 217 6 2.6 218 2.0
8 215 6 2.3 215 1.8
9 215 6 3.0 212 218 213 2.8
10 218 6 3.4 216 215 210 2.6
11 219 6 2.7 213 213 214 2.3
12 219 6 3.2 218 220 220 3.8
13 217 6 2.3 216 216 215 1.6
14 222 6 2.4 220 222 221 2.3
15 216 6 2.1 217 215 218 2.6
Mean fibrillatory intervals decreased at all recording areas in all patients. APD90 also decreased. RAA and CS were derived by
averaging two recording sites. D indicates change (value after verapamil administration minus baseline value).
APD90 5 monophasic action potential duration derived from Franz catheter; CS 5 coronary sinus; DC 5 dispersion
coefficient; RAA 5 right atrial appendage; RFW 5 right atrial free wall (mean fibrillatory interval derived by averaging eight
to 10 recording sites from decapolar catheter).
1406 Ramanna et al. JACC Vol. 37, No. 5, 2001
Verapamil and Chronic Atrial Fibrillation April 2001:1403–7
(8,10,11,18). During rapid pacing, L-type calcium channel
blockade prevents calcium influx and thus acute remodeling
(10). However, remodeling is associated not only with
calcium influx but also with changes in gap junction
distribution (3) and structural cellular (4,6,18) and meta-
bolic changes at a later stage. These changes may contribute
to a different response to verapamil at later stages of AF.
Conclusions. Although verapamil is effective for ventricu-
lar rate control, our data suggest that it is not useful for
reversing or preventing further remodeling in patients with
chronic AF. Verapamil did not alter the relationship be-
tween AF cycle length and APD90, suggesting that the
excitable gap during AF was not affected by verapamil.
Reprint requests and correspondence: Dr. Hemanth Ramanna,
Heart-Lung Institute, University Medical Center Utrecht, Hei-
delberglaan 100, 3584 CX Utrecht, Netherlands.
REFERENCES
1. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation
begets atrial fibrillation. A study in awake chronically instrumented
goats. Circulation 1995;92:1954–68.
2. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation
impairs sinus node function in dogs. Electrophysiological remodeling.
Circulation 1996;94:2953–60.
3. Elvan A, Huang XD, Pressler ML, Zipes DP. Radiofrequency
catheter ablation of the atria eliminates pacing-induced sustained atrial
fibrillation and reduces connexin 43 in dogs. Circulation 1997;96:
1675–85.
4. Ausma J, Wijffels MC, van Eys G, et al. Dedifferentiation of atrial
cardiomyocytes as a result of chronic atrial fibrillation. Am J Pathol
1997;151:985–97.
5. Yue L, Feng J, Gaspo R, Li GR, Wang Z, Nattel S. Ionic remodeling
underlying action potential changes in a canine model of atrial
fibrillation. Circ Res 1997;81:512–25.
6. Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms
underlying tachycardia-induced sustained atrial fibrillation in a chronic
dog model. Circulation 1997;96:4027–35.
7. Fareh S, Villemare C, Nattel S. Importance of refractoriness hetero-
geneity in the enhanced vulnerability to atrial fibrillation induction
caused by tachycardia-induced atrial electrical remodeling. Circulation
1998;98:2202–9.
8. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and
procainamide on atrial fibrillation-induced electrical remodeling in
humans. Circulation 1997;96:1542–50.
9. Crijns HJGM, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink
K, Lie KI. Serial antiarrhythmic drug therapy to maintain sinus
rhythm after electrical cardioversion for chronic atrial fibrillation or
atrial flutter. Am J Cardiol 1991;68:335–41.
10. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial
fibrillation. Time course and mechanisms. Circulation 1996;94:2968–
74.
11. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces
tachycardia-induced electrical remodeling of the atria. Circulation
1997;95:1945–53.
12. Shenasa M, Kus T, Fromer M, LeBlanc RA, Dubuc M, Nadeau R.
Effects of intravenous and oral calcium antagonists (diltiazem and
verapamil) on sustenance of atrial fibrillation. Am J Cardiol 1988;62:
403–7.
13. Lee SH, Yu WC, Cheng JJ, et al. Effect of verapamil on long-term
tachycardia-induced atrial electrical remodeling. Circulation 2000;101:
200–6.
14. Ramanna H, Hauer RNW, Wittkampf FHM, et al. Identification of
the substrate of atrial vulnerability in patients with idiopathic atrial
fibrillation. Circulation 2000;101:995–1001.
15. Opthof T, Ramdat Misier A, Coronel R, et al. Dispersion of
refractoriness in canine ventricular myocardium. Effects of sympathetic
stimulation. Circ Res 1991;68:1204–15.
16. Lammers WEJP, Schalij MJ, Kirchoff CJHJ, Allessie MA. Quantifi-
cation of spatial inhomogeneity in conduction and initiation of
reentrant atrial arrhythmias. Am J Physiol 1990;28:H1254–63.
17. Stambler BS, Wood MA, Ellenbogen KA. Antiarrhythmic actions of
intravenous ibitilide compared with procainamide during human atrial
fibrillation. Circulation 1997;96:4298–306.
18. Morillo CA, Klein GJ, Jones DL, Guiraudon CM. Chronic rapid
atrial pacing: structural, functional and electrophysiological character-
istics of a new model of sustained atrial fibrillation. Circulation
1995;91:1588–95.
19. Capucci A, Biffi M, Boriani G, et al. Dynamic electrophysiological
behavior of human atria during paroxysmal atrial fibrillation. Circula-
tion 1995;92:1193–1202.
20. Kim KB, Rodefeld MD, Schuessler RB, Cox JL, Boineau JP.
Relationship between local atrial fibrillation interval and refractory
period in the isolated canine atrium. Circulation 1996;94:2961–7.
21. Friedman HS, Rodney E, Sinha B, et al. Verapamil prolongs atrial
fibrillation by evoking an intense sympathetic neurohumoral effect.
J Invest Med 1999;47:293–303.
1407JACC Vol. 37, No. 5, 2001 Ramanna et al.
April 2001:1403–7 Verapamil and Chronic Atrial Fibrillation
